Moreover, ACE-inhibitor plus β-blocker treatment was reported to be more beneficial in patients with asymptomatic compared to those with symptomatic heart failure [27], and the combination therapy with an ACE-inhibitor or angiotensin receptor blocker plus β-blocker compared to mono-therapy was more favorable in DMD patients with abnormal left ventricular ejection fraction [28]. Here, ACE is linked to heart failure.